Calfactant

• Eisai presented Phase 1/2 data on E2814, an anti-tau drug, showing reduced levels of disease biomarkers in participants with mild to moderate genetic Alzheimer’s. • Roche terminated its agreement with UCB for beprenemab, an experimental tau-targeting antibody, after Phase 2 trial results showed it did not slow cognitive decline. • A Phase 2 trial of intranasal insulin and empagliflozin showed that insulin alone was associated with a small improvement in cognitive test performance in early Alzheimer’s patients.

• Eisai's E2814, an anti-tau drug, showed promise in reducing disease biomarkers in a Phase 1 trial involving participants with genetic Alzheimer's, warranting further studies. • Roche's trontinemab demonstrated effective amyloid reduction at high doses with a lower incidence of ARIA compared to other anti-amyloid antibodies in a Phase 1/2 trial. • UCB's beprenemab, a tau-targeting antibody, failed to slow cognitive decline in a Phase 2 trial, leading Roche to terminate their development and commercialization agreement. • Gene therapy LX001 from Lexeo Therapeutics showed early signs of success by increasing ApoE2 protein production and stabilizing amyloid levels in an ongoing Phase 1/2 study.